Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03621748
Other study ID # 18-005248
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date June 1, 2019
Est. completion date May 21, 2023

Study information

Verified date May 2023
Source Mayo Clinic
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study protocol examines a comparison between local and general anesthesia (Awake vs. Asleep Craniotomy) in the removal of brain tumors that are in areas of the brain that do not directly control bodily functions (non-eloquent gliomas).


Description:

This is a single-center, prospective randomized open or non-blinded end-point (PROBE) clinical trial. Patients will be selected by the neurosurgeon according to the inclusion and exclusion criteria. Patients who consent to randomization will have confirmed non-eloquent status confirmed by independent surgeon and will be randomized into 1 of 2 treatment groups utilizing a dynamic minimization approach. The experimental group with randomization of patients who will undergo awake craniotomy for both high and low grade gliomas in non-eloquent areas or a control group of patients who will have asleep craniotomy for both high and low grade gliomas in non-eloquent regions.


Recruitment information / eligibility

Status Completed
Enrollment 1
Est. completion date May 21, 2023
Est. primary completion date May 21, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility INCLUSION CRITERIA 1. Patients with age =18 years old. 2. WHO grade I, II, III, and IV Glioma in non-eloquent brain cortex based on magnetic resonance imaging (MRI) 3. An elective procedure. 4. A single lesion. 5. No major comorbidities that would necessitate an extended hospital stay. 6. Newly diagnosed tumors. EXCLUSION CRITERIA 1. Patients with age < 18 years old. 2. Non-gliomas 3. Eloquent location (motor, sensory, language) 4. Non-elective procedure. 5. Multiple lesions. 6. Major comorbidities. 7. Recurrent tumors. 8. Patients lacking capacity to consent.

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Awake Anesthesia Protocol
Awake is defined as the patient being awake with electrical brain stimulation mapping during the critical portions of the procedure.
Non-awake Anesthesia Protocol
Non-awake is general anesthesia as per convention with intubation.

Locations

Country Name City State
United States Mayo Clinic in Florida Jacksonville Florida

Sponsors (1)

Lead Sponsor Collaborator
Mayo Clinic

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Length of hospital stay (LOS) admission to discharge 0-30 days post operation
Other The Karnofsky Performance Score (KPS) ranking runs from 100 to 0, where 100 is "perfect" health and 0 is death Day 1 (+14 days), Post-operative up to 48 hrs, 3-6 weeks, 3mths, 6mths, and 9 mths
Other FACT-Br The FACT-Brain (FACT-Br) provides an additional set of disease-specific questions pertaining to brain neoplasms Day 1 (+14 days), Post-operative up to 48 hrs, 3-6 weeks, 3mths, 6mths, and 9 mths
Other Post-operative pain scale 0 to 10 (0: No pain, 10: Worst pain) - Numeric Scale Day 1 (+14 days), Post-operative up to 48 hrs, 3-6 weeks, 3mths, 6mths, and 9 mths
Other Cost of treatment Analysis to include standardized cost, physician service cost, cost of hospitalization and 30 days post-hospitalization cost captured until 30 days post operation
Primary Extent of resection Extent of resection (EOR) defined as the residual volume, in cm3, of tumor measured by MRI up to 48 hrs post operation
Secondary Percentage of baseline tumor volume resected Measured by MRI up to 48 hrs post operation
Secondary VAS Postoperative anxiety Postoperative Anxiety scale measured using a 0 to 10 visual analog scale (0: no anxiety, 10: worst anxiety) Day 1(+14 days) , Post op day 0, 1, 2 weeks, 3mth
Secondary Length of Surgery defined as time entering OR and leaving OR Intraoperative
See also
  Status Clinical Trial Phase
Recruiting NCT05556473 - F-Tryptophan PET/CT in Human Cancers Phase 1

External Links